Bifogade filer
PDF
Kurs
+6,25%
Likviditet
0,14 MSEK
Kalender
| Est. tid* | ||
| 2025-12-19 | 11:00 | Kvartalsrapport 2026-Q2 |
| 2025-10-17 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2025-10-16 | - | Årsstämma |
| 2025-09-26 | - | Kvartalsrapport 2026-Q1 |
| 2025-07-11 | - | Extra Bolagsstämma 2025 |
| 2025-06-26 | - | Bokslutskommuniké 2025 |
| 2025-03-13 | - | Kvartalsrapport 2025-Q3 |
| 2024-11-28 | - | Kvartalsrapport 2025-Q2 |
| 2024-10-12 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2024-09-16 | - | Kvartalsrapport 2025-Q1 |
| 2024-06-26 | - | Bokslutskommuniké 2024 |
| 2024-03-27 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-21 | - | Kvartalsrapport 2024-Q2 |
| 2023-11-15 | - | Extra Bolagsstämma 2024 |
| 2023-10-27 | - | Årsstämma |
| 2023-10-13 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2023-09-20 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-23 | - | Bokslutskommuniké 2023 |
| 2023-05-09 | - | Extra Bolagsstämma 2023 |
| 2023-03-28 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-21 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-31 | - | Årsstämma |
| 2022-10-14 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2022-09-29 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-29 | - | Bokslutskommuniké 2022 |
| 2022-03-21 | - | Kvartalsrapport 2022-Q3 |
| 2022-03-15 | - | Extra Bolagsstämma 2022 |
| 2021-12-29 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-10-11 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2021-09-29 | - | Kvartalsrapport 2022-Q1 |
| 2021-06-24 | - | Bokslutskommuniké 2021 |
| 2021-03-16 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-14 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-20 | - | Årsstämma |
| 2020-10-15 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2020-09-28 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-25 | - | Bokslutskommuniké 2020 |
| 2020-03-12 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-17 | - | Kvartalsrapport 2020-Q2 |
| 2019-10-16 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2019-10-15 | - | Årsstämma |
| 2018-09-27 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2018-09-26 | - | Årsstämma |
| 2018-06-18 | - | Extra Bolagsstämma 2019 |
| 2018-06-12 | - | Bokslutskommuniké 2018 |
| 2018-03-12 | - | Kvartalsrapport 2018-Q3 |
| 2017-09-26 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2017-09-25 | - | Årsstämma |
| 2017-09-11 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-19 | - | Bokslutskommuniké 2017 |
| 2017-03-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-01-01 | - | Extra Bolagsstämma 2018 |
| 2016-11-30 | - | Kvartalsrapport 2017-Q2 |
| 2016-09-06 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2016-09-05 | - | Årsstämma |
| 2016-09-05 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-13 | - | Bokslutskommuniké 2016 |
| 2016-02-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-16 | - | Extra Bolagsstämma 2017 |
| 2015-11-30 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-08 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2015-09-07 | - | Årsstämma |
| 2015-09-07 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-16 | - | Bokslutskommuniké 2015 |
| 2015-03-16 | - | Kvartalsrapport 2015-Q3 |
| 2014-12-01 | - | Kvartalsrapport 2015-Q2 |
| 2014-10-07 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2014-10-06 | - | Årsstämma |
| 2014-10-06 | - | Kvartalsrapport 2015-Q1 |
| 2014-06-30 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
NOVEMBER 2024 - JANUARY 2025
| Net sales | 6 481 (4 873) KSEK |
| Operating result before depreciation (EBITDA) | -987 (-3 179) KSEK |
| Net result | -2 681 (-5 152) KSEK |
| Earnings per share | -0.08 (-0.21) SEK |
| Gross margin | 76 (72) % |
MAY 2024 - JANUARY 2025
| Net sales | 10 796 (8 824) KSEK |
| Operating result before depreciation (EBITDA) | -8 510 (-9 568) KSEK |
| Net result | -12 280 (-14 826) KSEK |
| Earnings per share | -0.34 (-0.58) SEK |
| Gross margin | 71 (73) % |
IN SHORT
- Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year.
- Gross margin continues to be strong, even slightly above planned levels (+4pp).
- Overall costs remain stable and as per plan; higher admin costs (capital raise connected) vs. lower R&D expenses.
- The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline & company potential.
CEO Commentary
Having recently taken on the role of acting CEO at PHI, my primary focus is execution-translating the Company's potential into tangible results. We have a strong foundation built on deep technical expertise and a clear commitment to advancing regenerative medicine. Now, it's time to maximize that potential.
Our path forward is clear: be the best at what we know best. This means focusing on cutting-edge imaging technology that empowers cell research and therapy, supported by a strong distributor network and strategic partnerships. Our recent financial performance demonstrates that we are moving in the right direction, with growing sales and a strong gross margin. However, we must accelerate further, ensuring our innovations reach the market at scale.
With a committed team, solid industry relationships, and a clear mission, we are ready to take PHI to the next level. The focus now is on execution and delivering on our promises-because the opportunity ahead is too great not to seize.
Ivan Jurkovic, CEO
För ytterligare information, vänligen kontakta:
Ivan Jurkovic
E-mail: ir@phiab.com
Web: www.phiab.com - Live cell imaging & analysis